未找到相关数据
Overall survival and safety experience from an expanded access program (EAP) of nivolumab (NIVO) for patients with advanced melanoma (MEL) who progressed after prior ipilimumab (IPI) treatment
被引：1
作者：
Barros e Silva, Milton
Schmerling, Rafael
de Melo, Andreia Cristina
Azevedo, Sergio
Garicochea, Bernardo
McWhirter, Elaine
Smylie, Michael
Gifoni, Markus
dos Anjos, Carlos Henrique
Petrella, Teresa
Chacon, Matias
Greco, Martin
Nair, Suresh
Avila, Alexandre
Demelo, Sheena
Jiang, Joel
Ernst, Scott
机构：
来源：
关键词：
D O I：
10.1158/1538-7445.AM2017-LB-055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-055
引用
收藏
页数：2
相关论文